SAFC Biosciences and Chromos to Co-Market ACE System
News Oct 21, 2005
SAFC Biosciences, a member of the Sigma-Aldrich Group and Chromos Molecular Systems Inc. have entered into a non-exclusive co-marketing arrangement whereby SAFC Biosciences and Chromos will jointly market and offer Chromos' ACE System for cell line engineering for protein production applications.
This agreement adds to SAFC's process development service offerings for biopharmaceutical markets and expands Chromos' access to the global biopharmaceutical market with its ACE System.
“Chromos' ACE System is a unique and powerful vehicle for transferring genes into cells for the subsequent expression of proteins,” said Bruce Lehr, SAFC Biosciences.
“The ACE System demonstrates a significant improvement in cell engineering technology and gene expression.”
“Combined with SAFC Biosciences' cell culture media development expertise, biopharmaceutical customers can now achieve unparalleled speed in engineering cell lines and media development with the goal of maximizing protein output beyond what is achievable utilizing either technology separately.”
Alistair Duncan, President and CEO of Chromos said, “We believe the ACE System will be the platform of choice for rapidly engineering high-expressing cell lines for biopharmaceutical production.”
“This relationship will enable Chromos to leverage the extensive worldwide marketing and development expertise of SAFC Biosciences to increase the number of ACE System-based licenses and grow our cell line engineering business.”
“We are excited to be working with SAFC Biosciences, a highly respected international life sciences organization, and look forward to providing SAFC Biosciences customers with cell line engineering services using the ACE System.”
The agreement with Chromos will provide SAFC Biosciences' customers with access to the ACE System technology yielding a clear competitive advantage over currently available technology.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.